Pmv Pharmaceuticals Inc (PMVP) Stock Price, Quote & News

Company Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorpora...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 642 6670

Website: www.pmvpharma.com

Address:

400 Alexander Park Drive, Suite 301, Princeton, United States

GangsterX May. 22 at 4:17 PM

$PMVP $GERN slow shix!! never follow the market... i think it will move in June.. Just hold....

0 · Reply

OfficialStocktwitsUser May. 21 at 1:50 AM

$PMVP RSI: 42.31, MACD: -0.0250 Vol: 0.06, MA20: 1.38, MA50: 1.39 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

justiceforb_85 May. 13 at 7:32 PM

$PMVP good day to add. Rezatapopt has value, albeit the TAM is small.

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX $GERN $PMVP 3 biggies bet and still holding

1 · Reply

GangsterX May. 6 at 5:31 PM

$PMVP $GERN $REPL My 3 bigggesss... Looking good baby .... What did I say ??????

0 · Reply

GangsterX May. 6 at 3:07 PM

$PMVP I have big shix here.. This stock is slow shix... better move up...

0 · Reply

GangsterX May. 6 at 2:41 PM

$PMVP $GERN $REPL still holding 3 bigggies here

0 · Reply

chiefresident May. 3 at 5:58 PM

@Night_Owl_Biotech Have you researched $PMVP? very interesting company. early though.

1 · Reply

GangsterX May. 1 at 4:15 PM

$GERN $PMVP $REPL still holding all 3.. Biggies

0 · Reply

justiceforb_85 Apr. 29 at 8:41 PM

$PMVP added more. This should continue going up as we get more information from the FDA regarding a possible accelerated approval for rezatapopt in ovarian cancer TP53 Y220C mutation based on interval data.

0 · Reply

PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer

2026-05-12T16:19:03.000Z - 12 days ago

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

May 12, 2026, 8:00 AM EDT - 12 days ago

PMV Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 12 days ago

PMV Pharmaceuticals Earnings release: Q1 2026

2026-04-22T12:35:31.000Z - 4 weeks ago

PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed

KLRA

Apr 22, 2026, 8:00 AM EDT - 4 weeks ago

PMV Pharmaceuticals Announces Board Chair Transition

Apr 22, 2026, 8:00 AM EDT - 4 weeks ago

PMV Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 weeks ago

PMV Pharmaceuticals Proxy statement: Proxy filing

2026-04-13T13:54:36.000Z - 5 weeks ago

PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI

2026-03-06T13:13:11.000Z - 2 months ago

PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)

2026-03-06T13:12:36.000Z - 2 months ago

PMV Pharmaceuticals sees cash runway to end of 2Q27

Mar 6, 2026, 8:00 AM EST - 2 months ago

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 6, 2026, 7:00 AM EST - 2 months ago

PMV Pharmaceuticals Earnings release: Q4 2025

Mar 6, 2026, 7:00 AM EST - 2 months ago

PMV Pharmaceuticals Annual report: Q4 2025

Mar 2, 2026, 11:10 AM EST - 2 months ago

PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T13:14:32.000Z - 3 months ago

PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM

Feb 5, 2026, 7:00 AM EST - 3 months ago

PMV Pharmaceuticals Slides: Corporate presentation

2025-11-12T13:11:52.000Z - 6 months ago

PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)

Nov 12, 2025, 8:00 AM EST - 6 months ago

PMV Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 6 months ago

PMV Pharmaceuticals Quarterly report: Q3 2025

2025-10-24T15:50:14.000Z - 7 months ago

PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data

Oct 24, 2025, 11:39 AM EDT - 7 months ago

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Oct 13, 2025, 4:01 PM EDT - 7 months ago

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-09-10T11:05:34.000Z - 9 months ago

PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE

Sep 10, 2025, 7:00 AM EDT - 9 months ago

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

2025-08-07T12:45:49.000Z - 10 months ago

PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)

Aug 7, 2025, 8:42 AM EDT - 10 months ago

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 10 months ago

PMV Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

PMV Pharmaceuticals Earnings release: Q2 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

PMV Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 11:30 AM EDT - 1 year ago

PMV Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 23, 2025, 4:05 PM EDT - 1 year ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

2025-05-09T12:12:55.000Z - 1 year ago

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

2025-05-09T12:12:28.000Z - 1 year ago

PMV Pharmaceuticals sees cash runway to end of 2026

May 9, 2025, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Quarterly report: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Earnings release: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Mar 4, 2025, 3:10 PM EST - 1 year ago

PMV Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

2025-03-03T13:11:53.000Z - 1 year ago

PMV Pharmaceuticals sees cash runway to end of 2026

2025-03-03T13:05:19.000Z - 1 year ago

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)

Mar 3, 2025, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Mar 3, 2025, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Earnings release: Q4 2024

Feb 12, 2025, 3:18 PM EST - 1 year ago

PMV Pharmaceuticals Slides: Corporate Presentation

Feb 12, 2025, 12:40 PM EST - 1 year ago

PMV Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

2024-11-20T13:05:16.000Z - 1 year ago

PMV Pharmaceuticals files $200M mixed securities shelf

Nov 20, 2024, 7:00 AM EST - 1 year ago

PMV Pharmaceuticals Registration statement: Registration Filing

2024-11-08T11:30:21.000Z - 1 year ago

PMV Pharmaceuticals upgraded at Oppenheimer ahead of rezatapopt readout

2024-11-08T11:10:54.000Z - 1 year ago

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

2024-11-07T13:09:40.000Z - 1 year ago

PMV Pharmaceuticals reports Q3 EPS (37c), consensus (35c)

2024-11-07T13:09:19.000Z - 1 year ago

PMV Pharmaceuticals sees cash runway to end of 2026

Nov 7, 2024, 7:00 AM EST - 1 year ago

PMV Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

PMV Pharmaceuticals Earnings release: Q3 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

PMV Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

PMV Pharmaceuticals Earnings release: Q2 2024

May 29, 2024, 7:00 AM EDT - 2 years ago

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

May 9, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 7:00 AM EDT - 2 years ago

PMV Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

PMV Pharmaceuticals Earnings release: Q1 2024

Apr 24, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Mar 27, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Mar 18, 2024, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Mar 18, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Press release: FY 2024

Mar 18, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Slides: FY 2024

Feb 29, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Feb 29, 2024, 7:00 AM EST - 2 years ago

PMV Pharmaceuticals Annual report: Q4 2023

Feb 29, 2024, 7:00 AM EST - 2 years ago

PMV Pharmaceuticals Earnings release: Q4 2023

Jan 18, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Jan 5, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Nov 9, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 7:00 AM EST - 2 years ago

PMV Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

PMV Pharmaceuticals Earnings release: Q3 2023

Oct 12, 2023, 12:30 PM EDT - 2 years ago

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Oct 12, 2023, 7:00 AM EDT - 2 years ago

PMV Pharmaceuticals Slides: KOL Presentation

Oct 11, 2023, 12:00 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

Oct 11, 2023, 7:00 AM EDT - 2 years ago

PMV Pharmaceuticals Slides: Study Update

Sep 20, 2023, 4:05 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 9, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 9, 2023, 7:00 AM EDT - 3 years ago

PMV Pharmaceuticals Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

PMV Pharmaceuticals Earnings release: Q2 2023

Jun 6, 2023, 4:01 PM EDT - 3 years ago

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

May 10, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

May 10, 2023, 7:00 AM EDT - 3 years ago

PMV Pharmaceuticals Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

PMV Pharmaceuticals Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Mar 1, 2023, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Mar 1, 2023, 7:00 AM EST - 3 years ago

PMV Pharmaceuticals Annual report: Q4 2022

Mar 1, 2023, 7:00 AM EST - 3 years ago

PMV Pharmaceuticals Earnings release: Q4 2022

Feb 28, 2023, 4:05 PM EST - 3 years ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Nov 22, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Nov 8, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Nov 8, 2022, 7:00 AM EST - 3 years ago

PMV Pharmaceuticals Earnings release: Q3 2022

Nov 8, 2022, 7:00 AM EST - 3 years ago

PMV Pharmaceuticals Quarterly report: Q3 2022

Nov 8, 2022, 7:00 AM EST - 3 years ago

PMV Pharmaceuticals Press release: Q3 2022

Nov 4, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

Aug 9, 2022, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Aug 9, 2022, 7:00 AM EDT - 4 years ago

PMV Pharmaceuticals Quarterly report: Q2 2022

Aug 9, 2022, 7:00 AM EDT - 4 years ago

PMV Pharmaceuticals Earnings release: Q2 2022

Jul 18, 2022, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Jun 7, 2022, 12:00 PM EDT - 4 years ago

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

May 26, 2022, 5:05 PM EDT - 4 years ago

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2022, 7:30 AM EDT - 4 years ago

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

May 10, 2022, 7:00 AM EDT - 4 years ago

PMV Pharmaceuticals Quarterly report: Q1 2022

May 10, 2022, 7:00 AM EDT - 4 years ago

PMV Pharmaceuticals Earnings release: Q1 2022

Apr 27, 2022, 10:30 AM EDT - 4 years ago

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 22, 2022, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Mar 1, 2022, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Feb 28, 2022, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

Feb 3, 2022, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

Jan 6, 2022, 8:00 AM EST - 4 years ago

PMV Pharma Announces Changes to its Board of Directors

Nov 22, 2021, 8:00 AM EST - 4 years ago

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

Nov 12, 2021, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Sep 2, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Aug 13, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Jun 9, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

May 14, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

May 5, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

Apr 23, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Proxy statement: Proxy Filing

Apr 10, 2021, 1:31 PM EDT - 5 years ago

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Apr 6, 2021, 8:00 AM EDT - 5 years ago

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

Mar 10, 2021, 4:31 PM EST - 5 years ago

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 3, 2021, 4:01 PM EST - 5 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Feb 16, 2021, 8:00 AM EST - 5 years ago

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Nov 24, 2020, 5:00 PM EST - 5 years ago

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

GangsterX May. 22 at 4:17 PM

$PMVP $GERN slow shix!! never follow the market... i think it will move in June.. Just hold....

0 · Reply

OfficialStocktwitsUser May. 21 at 1:50 AM

0 · Reply

justiceforb_85 May. 13 at 7:32 PM

$PMVP good day to add. Rezatapopt has value, albeit the TAM is small.

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX $GERN $PMVP 3 biggies bet and still holding

1 · Reply

GangsterX May. 6 at 5:31 PM

$PMVP $GERN $REPL My 3 bigggesss... Looking good baby .... What did I say ??????

0 · Reply

GangsterX May. 6 at 3:07 PM

$PMVP I have big shix here.. This stock is slow shix... better move up...

0 · Reply

GangsterX May. 6 at 2:41 PM

$PMVP $GERN $REPL still holding 3 bigggies here

0 · Reply

chiefresident May. 3 at 5:58 PM

@Night_Owl_Biotech Have you researched $PMVP? very interesting company. early though.

1 · Reply

GangsterX May. 1 at 4:15 PM

$GERN $PMVP $REPL still holding all 3.. Biggies

0 · Reply

justiceforb_85 Apr. 29 at 8:41 PM

0 · Reply

GangsterX Apr. 24 at 8:47 PM

$PMVP $GERN $REPL still holding.. 3 biggies

0 · Reply

DARKP00L Apr. 22 at 12:05 PM

$PMVP 08:03 on Apr. 22 2026 PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman #tradeideas

0 · Reply

justiceforb_85 Apr. 16 at 2:14 AM

$PMVP don't understand why this continues to trade under cash.

1 · Reply

GangsterX Apr. 14 at 4:30 PM

$PMVP This is just the beginning. You’ll see big shix in a couple of months. If I’m here, there’s nothing to worry about....only big $$$ in the bank. That’s why people on StockTwits always call me as “KungFu Trader.”

0 · Reply

GangsterX Apr. 14 at 4:14 PM

$GERN $PMVP $REPL still holding. They are all my biggies one

1 · Reply

GangsterX Apr. 13 at 6:40 PM

$GERN $PMVP they are my bigggies.. Never Sell

0 · Reply

GangsterX Apr. 9 at 8:05 PM

$PMVP $GERN $ALLO still holding all 3 but i sold ALLO half. pMVP will run up soon

0 · Reply

justiceforb_85 Mar. 13 at 5:12 PM

$PMVP holding steady.

0 · Reply

GangsterX Mar. 10 at 2:37 PM

$PMVP avg 1.17 and still holding.. Biggie here

0 · Reply

GangsterX Mar. 10 at 2:17 PM

$GERN $PMVP Hold for couple months. Stilll good

1 · Reply

GangsterX Mar. 9 at 7:02 PM

$GERN $PMVP holding biggies on those 2. pT 3

0 · Reply

Merlintrader Mar. 7 at 8:47 PM

$PMVP https://www.merlintrader.com/pmv-pharmaceuticals-inc-pmvp/

0 · Reply

Market Cap	67.20M
Revenue (ttm)	0.00
Net Income (ttm)	-77.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	163,200
Avg Vol	410,178
Day's Range	N/A - N/A
Shares Out	53.33M
Stochastic %K	13%
Beta	1.41
Analysts	Strong Sell
Price Target	$4.50